Ignite Creation Date:
2024-05-06 @ 7:34 PM
Last Modification Date:
2024-10-26 @ 3:09 PM
Study NCT ID:
NCT06056830
Status:
RECRUITING
Last Update Posted:
2024-05-31
First Post:
2023-09-21
Brief Title:
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants with High-risk Prostate Cancer Prior to Radical Prostatectomy
Sponsor:
Clarity Pharmaceuticals Ltd
Organization:
Clarity Pharmaceuticals Ltd
Study Overview
Official Title:
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants with High-risk Prostate Cancer Prior to Radical Prostatectomy a Prospective Single-arm Multi-center Blinded-review Phase 3 Diagnostic Performance Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CLARIFY
Brief Summary:
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None